Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous skin substitute for therapy-resistant leg ulcers
NL-OMON40033Phase 2Active, not recruiting
- Sponsor
- Amsterdam UMC
- Start
- Jun 2012
- Modality
- Cell Therapies, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in stasis ulcer and Mixed venous-arterial leg ulcer (MVALU) comparing Tiscover with AS210 (2 arms). Primary endpoints: Time to heal, Ulcer closure at week 12 and 3 more. Started Jun 2012; status: active, not recruiting.
02
Drugs
TiscoverAS210
03
Conditions
stasis ulcerMixed venous-arterial leg ulcer (MVALU)
Beyond the preview
Go deeper on NL-OMON40033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40033.